Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review for idecabtagene vicleucel.
Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on […]
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
A study published in the scientific journal Nature explains why certain kinds of cancer cells often spread to the lymph nodes before various organs within the body.
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program, including the extended half-life cytokine DF6002 as a potential treatment for solid and hematological cancers.
Published research in the peer-reviewed scientific journal Cell outlines a way to make even immunotherapy-resistant cancers treatable.
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival in patients with previously untreated, unresectable malignant pleural mesothelioma in the Phase 3 CheckMate -743 clinical trial.
The U.S. Food and Drug Administration issued a Complete Response Letter regarding DBV Technologies’ Biologics License Application (BLA) for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
A strategic collaboration was inked that will combine BioNTech’s BNT111 FixVac product candidate and Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab) for the treatment of melanoma.
Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.